Introduction
Idiopathic membranous nephropathy (IMN) is the complete or partial disappearance of nephrotic syndrome.6 most common form of glomerular disease causing nephrotic syndrome in adults.1 While many patients Specific treatment with immunosuppressive agents, however, is not without morbidity and potenhave a spontaneous remission of the disease and reduction of proteinuria with time, a significant tial mortality, and not all patients respond. Moreover, as most of the published data are derived from the proportion develop severe and persistent proteinuria, and progress to chronic renal failure or end-stage Caucasian population, little is known about the clinical course and treatment outcome of IMN renal disease.1-3 Reports of the natural history of the disease have yielded different results owing to variamongst Chinese patients in the Far East. To shed light on the natural course of the disease and the ations in patient population, geographical location, method of patient monitoring, and duration of followinfluence of different forms of therapy, we retrospectively reviewed the outcome of all patients with a up.4,5 Though the optimal treatment of IMN remains uncertain, Couchoud et Eight had hepatitis B surface antigenaemia, two had Group I comprised eight patients who received malignant conditions within 18 months of diagnosis, supportive treatment alone and never received any two had rheumatoid arthritis, one died of acute specific (immunosuppressive) therapy. Group II commyocardial infarction shortly after diagnosis, two prised seven patients who received oral corticosteroid lived in old-age homes and could not be followed alone, given in the form of prednisolone starting at regularly, one chose to take Chinese herbal medicine 0.5 mg/kg/day and tapered over a period of [6] [7] [8] [9] and defaulted follow-up, one was a drug addict with months (median 7 months) according to response to doubtful compliance, while two of four patients who therapy. Group III comprised 17 patients who were already near end-stage renal failure at presentareceived corticosteroid plus cyclophosphamide.
tion received a renal transplant in less than 6 months Corticosteroid was given orally as in group II. from diagnosis. All these patients were excluded Cyclophosphamide was given orally at 1 mg/kg/day from the study. The epidemiological and clinical and stopped after 6-12 months (median 6 months) characteristics of the remaining 38 patients with IMN regardless of response. None of the patients in this are summarized in Table 1 . group received either drug intravenously. Group IV As the patients were recruited over a 10-year comprised six patients who received corticosteroid study period, two different time points were chosen and chlorambucil alternately for 6 months according to reflect their short-term (after 6 months of therapy) to a protocol designed by Ponticelli et al. 7 Briefly, and long-term (after 5 years of diagnosis) clinical 500 mg of methylprednisolone was infused intravenoutcomes. At 6 months, two patients (25%) were in ously daily for 3 days followed by oral prednisolone complete remission and one (14%) in partial remis-0.5 mg/kg/day for 27 days at months 1, 3, and 5, sion in group I, but the degree of proteinuria and alternating with chlorambucil 0.2 mg/kg/day for 30 serum albumin levels as a group were not significdays at months 2, 4, and 6.
antly altered. Five patients (71%) in group II were in All patients were monitored at 1-3-monthly interremission, complete in two (29%) and partial in vals depending on individual need and disease three (42%). In group III, 11 patients (65%) remitted; severity. During each visit, plasma creatinine and complete remission was observed in four (24%), and serum albumin, complete blood count, urinary propartial remission in seven patients (41%). In group IV, complete remission was present in one (17%), and tein excretion either in the form of dipstick testing Values are means±SD.
partial remission in two patients (33%). In groups II predicting renal function deterioration, while other factors did not correlate significantly with subsequent through IV, there was a significant reduction in proteinuria, with a corresponding rise in serum changes in plasma creatinine. No significant complication was recorded among albumin compared with baseline levels (Figures 1  and 2) .
patients of groups I and II. In group III, one patient with persistent nephrotic syndrome died of myocardTo eliminate bias as a result of a difference in the length of follow-up, we analysed the long-term ial infarction 14 months after presentation, one patient with renal insufficiency had a cerebrovascular outcome at 5 years among those patients who had been followed for this period of time or longer. As accident 30 months after presentation, and another patient developed carcinoma of the colon requiring only three group II and two group IV patients had been followed for over 5 years, they were excluded a right hemicolectomy 5 years after presentation while in partial remission. One group IV patient had for this evaluation. Among six group I (median follow-up 64 months) and eight group III (median a severe episode of pneumonia 6 years after presentation, requiring intensive care. In particular, none of follow-up 81 months) patients who had been followed for at least 5 years, the serum creatinine the patients in all the three treatment groups had their medications reduced or terminated because almost remained unchanged in both groups (Figure 3 ), but there was a progressive reduction in of drug-related side-effects, although one patient reported mild gastrointestinal upset in the second the amount of proteinuria in group III patients over the follow-up period. This improvement was not cycle of chlorambucil. Apart from the patient who died from myocardial infarction, none of the patients observed in group I (Figure 4 ). However, due to the relatively small patient numbers and the high standin all groups had any thrombotic episodes, noting that over 40% still had a daily urinary protein ard deviation, this difference was only just significant ( p=0.048).
excretion of more than 2 g at 12 months. Renal function deterioration occurred in one patient in each of group I (13%), group III (6%) and group IV (17%) during the follow-up period. In Discussion group II, two (29%) had renal function deterioration, of whom one required renal replacement therapy 2
The aim of this retrospective study was to give an overview on the clinical course, and treatment years after presentation ( Figure 5) . To assess the impact of different factors on renal function deterioraoutcome of idiopathic membranous nephropathy amongst Chinese patients, on whom such data, to tion, the following variables were taken into account: sex, age, presenting plasma creatinine levels, proour knowledge, are lacking in the literature. While drugs, systemic lupus erythematosus, and teinuria, blood pressure, tubulointerstitial scarring on renal biopsy. Univariate survival analysis showed rheumatoid arthritis are the conditions most frequently associated with membranous glomerulothat an elevated presenting plasma creatinine level ( p<0.05) was the single most important factor in nephritis in Western society,8,9 hepatitis B surface antigenaemia remains the strongest association in the locality of Hong Kong, where 10% of its population of 6 million people are carriers of the virus.10 Though a direct causal relationship between the levels between the untreated (group I) and the treated (groups II, III, IV) patients. There was no difference virus and membranous nephropathy may be difficult to establish, it was reflected by the higher prevalence in the creatinine values in the four groups of patients. Overall, our results show that IMN runs a benign of the carrier state among membranous nephropathy patients in this series (13.6%) compared to the course for most patients in the locality of Hong Kong. While 13% (5/38) of patients developed renal general population (10%) in Hong Kong and southern China.
function deterioration over a period of 60 months, only 2.6% (1/38) went into end-stage renal failure Because of the length of time over which patients were included in the present analysis, the treatment requiring dialysis. Given the risks associated with immunosuppression, it is justifiable to elect only regimen reflected our views at different times. In general, a policy of treating only those patients with those patients with severe persistent nephrotic syndrome or significant progressive renal failure for heavy proteinuria applied. This explains the difference in the presenting proteinuria and serum albumin treatment. This could explain the relative lack of trols in a randomized fashion. Nevertheless, our results are in sharp contrast to those obtained from Caucasians, in whom corticosteroid alone for 6 months failed to achieve any difference between treatment and control groups in terms of creatinine clearance and 24-h urinary protein excretion.11,12 Although in our series steroid alone induced remission in up to 71% of patients, it did not offer as much renal function protection as the other form of treatment, as reflected by the fact that 6% in group III vs. 29% in group II had developed renal function deterioration, noting that both groups had a comparable degree of proteinuria and serum creatinine at ciency in idiopathic membranous nephropathy, they appear late, are not quantitative in nature and have not been validated.13 Initial serum creatinine levels, singled out as an important prognosticator in subsequent renal function deterioration, thus have potential implications in guiding the form of treatment any individual patient should receive. This concept of stratifying patients on presentation as to their risk of developing renal failure has been alluded to in a recent review.8 Although most patients were severely nephrotic at presentation (Table 1) , none developed renal vein thrombosis, a common complication of the nephrotic syndrome,14 despite the absence of anticoagulant prophylaxis that would otherwise have been given warfarin and a lower target of international normalized ratio (INR) than their Caucasian counterparts as a prophylaxis against thromboembolic complications.15,16 While leukopaenia and gastrointestinal upset are frequent causes of interrupting chlorambucil in Caucasian patients,8 they are uncommon in Chinese patients, although the number of patients receiving chlorambucil was comparatively small in our series.
This study has highlighted the categorical differences in clinical features and treatment outcomes with IMN. The form of treatment that gives the best results in the former may not apply in the latter. difference in the outcome between treated and Whether Chinese patients are 'more sensitive' to untreated patients in this series.
immunosuppressives and hence require less immunoWith regard to reduction of proteinuria, it is suppression to achieve and sustain remission of IMN apparent that steroid alone, steroid plus cyclophoshas yet to be investigated by a randomized and phamide, and steroid alternating with chlorambucil controlled prospective study. have all been effective given the comparable degree of initial proteinuria in groups II, III and IV patients.
